Olsen E A, Abernethy M L, Kulp-Shorten C, Callen J P, Glazer S D, Huntley A, McCray M, Monroe A B, Tschen E, Wolf J E
Duke University Medical Center, Durham, NC 27710.
J Am Acad Dermatol. 1991 May;24(5 Pt 1):738-43. doi: 10.1016/0190-9622(91)70113-g.
This double-blind, vehicle-controlled, multicenter study evaluated the efficacy and safety of a new topical antineoplastic agent, masoprocol, in the treatment of actinic keratoses of the head and neck. Of the 113 patients who applied topical masoprocol twice a day for 14 to 28 days, there was a mean decrease in actinic keratoses from 15.0 to 5.4 and a median percent reduction from baseline actinic keratosis count of 71.4% at the 1-month follow-up visit. Comparable numbers for the vehicle-treated group were 13.4 to 11.1 actinic keratoses and 4.3% median percent reduction. Irritation, as manifested by erythema or flaking, occurred in 61.5% of topical masoprocol-treated patients versus 26.7% of those treated with vehicle and did not correlate with clinical response. Topical masoprocol appears to be useful in the treatment of actinic keratoses.
这项双盲、赋形剂对照、多中心研究评估了一种新型局部抗肿瘤药马索罗酚治疗头颈部光化性角化病的疗效和安全性。在113例每天两次外用马索罗酚、持续14至28天的患者中，光化性角化病平均从15.0处减少至5.4处，在1个月随访时，与基线光化性角化病计数相比，中位数减少百分比为71.4%。赋形剂治疗组的相应数字为光化性角化病从13.4处减少至11.1处，中位数减少百分比为4.3%。外用马索罗酚治疗的患者中61.5%出现以红斑或脱屑为表现的刺激反应，而赋形剂治疗患者中这一比例为26.7%，且刺激反应与临床疗效无关。外用马索罗酚似乎对头颈部光化性角化病的治疗有效。
